83 / 89
83
cutaneous systemioc sclerosis – a retrospective
analysis. Rheumatology (Oxford) 2007;46:442-
5.
107.
Avouac J, Airò P, Meune C, Beretta L, Dieude
P, Caramaschi P, et al. Prevalence of
pulmonary hypertension in systemic sclerosis
in European Caucasians and metaanalysis of 5
studies. J Rheumatol 2010;37:2290-8.
108.
Badesch DB, Tapson VF, McGoon MD,
Brundage BH, Rubin LJ, Wigley FM, et al.
Continuous intravenous epoprostenol for
pulmonary
hypertension
due
to
the
scleroderma
spectrum
of
disease.
A
randomized, controlled trial. Ann Intern Med
2000;132:425-34.
109.
Caravita S, Wu SC, Secchi MB, Dadone B,
Bencini C, Pierini S. Long-term effects of
intermittent Iloprost infusion on pulmonary
arterial pressure in connective tissue disease.
Eur J Int Med 2011;22:518-21.
110.
Channick RN, Simonneau G, Sitbon O,
Robbins IM, Frost A, Tapson VF, et al. Effects
of the dual endothelin-receptor antagonist
bosentan in patients with pulmonary
hypertension:
a
randomised
placebo-
controlled study. Lancet 2001;358:1119-23.
111.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black
CM, Keogh A, et al. Bosentan therapy for
pulmonary arterial hypertension. N Engl J
Med 2002;346:896-903.